Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell entities : Takeda pharmaceutical company limited save search
Novel T-Cell Immunotherapies Market - Future Pipeline/Clinical Trial Analysis and Revenue Forecast Snapshot - Exclusive Report by InsightAce Analytic
Published: 2022-06-23 (Crawled : 08:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 1.56%
H: 0.73%
C: 0.44%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 4.14%
H: 0.0%
C: 0.0%
report t-cell trial market
Egle Therapeutics Raises 40 Million € Series a to Develop First-In-Class T-regulatory Cells Therapies Based On Treg-starvers
Published: 2021-10-22 (Crawled : 11:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: -0.41%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.07%
H: 0.5%
C: 0.29%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
therapy
GammaDelta Therapeutics Receives FDA Clearance of IND Application for GDX012, a Novel Allogeneic Variable Delta 1 Gamma-delta T Cell Cancer Therapy
Published: 2021-05-20 (Crawled : 11:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.82%
H: 0.81%
C: 0.23%
fda clearance fda therapy cancer application clearance t-cell
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.